Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedSep 27, 2023
DataAggregated Company Financials
  • 7D-3.0%
  • 3M-13.0%
  • 1Y-41.8%
  • YTD-42.3%

Over the last 7 days, the Biotech industry has dropped 6.1%, driven by Idorsia declining 15%. The industry has fallen 42% in the last year. As for the next few years, earnings are expected to grow by 7.5% per annum.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 27 Sep 2023CHF263.1mCHF318.9m-CHF219,592,353.00n/a-1.2x0.8x
Fri, 25 Aug 2023CHF298.5mCHF330.3m-CHF177,182,325.00n/a-1.7x0.9x
Sun, 23 Jul 2023CHF326.7mCHF321.5m-CHF179,828,989.00n/a-1.8x1x
Tue, 20 Jun 2023CHF314.1mCHF330.4m-CHF180,808,144.00n/a-1.7x1x
Thu, 18 May 2023CHF352.4mCHF330.2m-CHF183,173,955.00n/a-1.9x1.1x
Sat, 15 Apr 2023CHF425.3mCHF491.2mCHF8.2m1.6x51.9x0.9x
Mon, 13 Mar 2023CHF464.5mCHF494.3mCHF15.0m1.6x31x0.9x
Wed, 08 Feb 2023CHF503.5mCHF493.4mCHF14.5m1.7x34.7x1x
Fri, 06 Jan 2023CHF500.3mCHF493.4mCHF14.5m1.7x34.5x1x
Sun, 04 Dec 2022CHF525.8mCHF493.4mCHF14.5m1.9x36.3x1.1x
Tue, 01 Nov 2022CHF510.1mCHF510.1mCHF14.8m1.8x34.4x1x
Thu, 29 Sep 2022CHF516.5mCHF504.9mCHF15.9m1.9x32.4x1x
Sat, 27 Aug 2022CHF500.6mCHF488.0mCHF36.1m1.8x13.9x1x
Mon, 25 Jul 2022CHF529.5mCHF486.8mCHF42.3m1.8x12.5x1.1x
Wed, 22 Jun 2022CHF523.6mCHF456.6mCHF81.1m2.1x6.5x1.1x
Fri, 20 May 2022CHF720.1mCHF470.3mCHF25.0m2x28.8x1.5x
Sun, 17 Apr 2022CHF1.1bCHF291.5m-CHF142,580,258.001.9x-7.7x3.8x
Tue, 15 Mar 2022CHF1.3bCHF284.2m-CHF140,782,084.001.9x-9x4.5x
Thu, 10 Feb 2022CHF4.6bCHF318.4m-CHF658,875,581.001.8x-7x14.4x
Sat, 08 Jan 2022CHF4.7bCHF317.7m-CHF658,979,620.001.5x-7.1x14.7x
Mon, 06 Dec 2021CHF3.8bCHF317.4m-CHF659,021,385.001.5x-5.7x11.8x
Wed, 03 Nov 2021CHF4.3bCHF315.5m-CHF658,911,116.002.3x-6.5x13.6x
Fri, 01 Oct 2021CHF5.3bCHF288.9m-CHF590,639,030.004.9x-8.9x18.2x
Sun, 29 Aug 2021CHF5.1bCHF306.0m-CHF612,309,374.801.1x-8.4x16.8x
Mon, 05 Jul 2021CHF5.8bCHF306.0m-CHF612,309,374.801.1x-9.4x18.8x
Thu, 08 Apr 2021CHF6.2bCHF352.3m-CHF535,605,963.803.8x-11.6x17.7x
Sun, 10 Jan 2021CHF6.1bCHF407.2m-CHF561,055,198.507.1x-10.9x15x
Sat, 03 Oct 2020CHF5.7bCHF399.6m-CHF565,530,866.501x-10.1x14.3x
Price to Earnings Ratio


Total Market Cap: CHF5.7bTotal Earnings: -CHF565,530,866.50Total Revenue: CHF399.6mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average 3.3x202120222023
Current Industry PE
  • Investors are pessimistic on the Swiss Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 8.1x is higher than the industry's current PS ratio of 0.83x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 7.3% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Comparison

How does Swiss Biotech compare with similar industries?

CH Market-1.29%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MOLN Molecular PartnersCHF3.910.8%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.